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The standard treatment choice for cancer metastasis has been systemic management, including cytotoxic
chemotherapy, hormonal manipulation, and targeted therapy. Emerging evidence has shown an oligometastatic
state, an intermediate state between limited primary cancer and polymetastatic cancer, in which local therapy for
metastatic lesions results in satisfactory survival comparable to non-metastatic disease. We provide a comprehensive
introduction of evidence from experimental and clinical studies in favor of the oligometastatic phenotype, we review
the efficacy and safety of surgery and stereotactic body radiotherapy in the treatment of oligometastases, and finally,
we discuss the way to differentiate the oligometastatic state from polymetastasis.
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Cancer is widely regarded as a systemic disease. Previ-
ously, cancer with metastasis has been considered stage
IV, an end-stage disease, with the goal of palliative man-
agement. The standard treatment choice for metastatic
cancer has been systemic management, including cyto-
toxic chemotherapy, hormonal manipulation, and targeted
therapy. Despite recent advances in systemic therapy,
prognosis remains poor. Within the population of cancer
metastasis, emerging evidence has shown that a fraction
of patients have an oligometastatic state, in which local
therapy for metastatic lesions results in satisfactory sur-
vival comparable to non-metastatic disease. The concept
of an oligometastatic state was first proposed by Hellman
et al. as an intermediate state (≤5 metastases) between
limited primary and polymetastatic cancers in which local
therapy could achieve long-term survival or cure, with no
restrictions on primary lesions [1,2]. In 2006, the concept
of oligo-recurrence was defined by Niibe et al. as the state
that cancer patients have ≤5 metastatic or recurrent le-
sions with controlled primary lesions [3]. Recently, the
concept of sync-oligometastasis was proposed as the
state that cancer patients have ≤5 metastatic or recur-
rent lesions with active primary lesions [4]. The major
difference among oligometastasis, oligo-recurrence and* Correspondence: xhzlwg@163.com; yangky71@aliyun.com
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unless otherwise stated.sync-oligometastasis was the status of the primary le-
sion, which is the most important prognostic factor of
oligometastasis, and oligo-recurrence showed better
prognosis compared with sync-oligometastasis.
Despite the accumulating knowledge on this state, the
existence of oligometastasis remains debatable. Although
oligometastatic clones are not identified directly, some
clonal areas with modest metastatic capacities might
lead to oligometastasis, at least in a fraction of all meta-
static cases. During the past decades, a large amount of
data has shown excellent 5-year survival rates after ag-
gressive local treatment of metastatic disease for many
patients, including those with a limited number of me-
tastases, certain primary tumor types, and early T- and
N-stage primary tumors. However, many oncologists be-
lieve oligometastasis is more like a mirage than a reality.
In this review, we provide a comprehensive introduction
of evidence favoring the oligometastatic phenotype, we
review the efficacy and safety of two methods to treat
metastatic lesions [surgery and stereotactic body radiother-
apy (SBRT)], and finally, we discuss the manner in which
oligometastasis can be differentiated from polymetastasis.Review
Biological basis of the oligometastatic phenotype
Metastasis occurs when genetically unstable cancer cells
colonize a tissue microenvironment distant from the
primary tumor. With advances in genomic researchLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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high-resolution genome-wide SNP and copy number
analyses, emerging evidence indicates that clones with
selective advantages within the primary tumor give rise
to distant metastasis. Navin et al. applied single-nucleus
sequencing to investigate the genetic relationship between
a primary breast cancer tumor and its liver metastasis [5],
they found that copy number profiles from the primary
tumor were highly similar to those from the metastases,
indicating that metastatic cells emerge from a main ad-
vanced expansion rather than from an earlier intermediate
or a completely different subpopulation.
Primary tumors are composed of heterogeneous cell
populations, and evidence over the years has shown that
tumor clones are not equally able to metastasize. Fidler
et al. identified a wide range of metastatic ability of
B16F1 melanoma cells to colonize the lung [6], support-
ing the notion of clonal heterogeneity within the primary
tumor. Various cell lines with high and low metastatic
potential have also been reported in PC-14 human
lung adenocarcinoma cells [7] and MHCC97 hepato-
cellular carcinoma cells [8], and these results have
been expanded upon by investigators using KHT sar-
coma cells [9].
Further important evidence implying the existence of
oligometastasis was proposed by Yachida et al. who used
next-generation sequencing techniques to analyze the
genomes of seven patients with pancreatic cancer metas-
tases in order to evaluate the clonal relationships between
the primary and metastatic cancers [10]. Quantitative ana-
lysis of the genetic evolution of pancreatic cancer indi-
cated at least a decade between the initiating mutation
and the birth of the cancer cell, another five years were re-
quired for acquisition of metastatic ability. This temporal
nature emphasizes that oligometastastic clones might de-
velop before polymetastatic clones during tumorigenesis.
During this time, intensive research on metastasis-
regulating genes has also advanced. Although the genes
responsible for the oligometastastic phenotype remain
elusive, DNA array analysis has provided important in-
formation to distinguish oligometastasis from polyme-
tastasis. Wuttig et al. used samples from patients with
renal cell carcinoma to identify genes that characterized
‘few’ (<8) or ‘many’ (>16) pulmonary metastases [11].
Analysis of fresh samples from resection of pulmonaryTable 1 Summary of hepatic metastasectomy from selected s
Primary tumor type Year No. pat
Noncolorectal 2005 142
Noncolorectal Nonendocrine liver metastases 2006 1452
Noncolorectal nonneuroendocrine liver metastases 2007 360
Breast cancer 2010 41
Soft-tissue sarcoma 2009 45metastases revealed 135 genes that were differentially
expressed between the ‘few’ and ‘many’ metastasis groups.
Furthermore, polymetastatic tumors were enriched by
genes that regulate the cell cycle. Based on a meta-analysis
of these data and previously published data, an 11-gene
classifier was established to predict the number of metas-
tases in patients with renal cell carcinoma. These data
provide evidence at the molecular level for the existence
of an oligometastastic state, but further work is essential
to clarify mechanisms that generate the oligometastastic
phenotype.
Clinical supporting evidence and treatment options for
oligometastases
Liver oligometastases
The liver is frequently involved in cancer metastasis, es-
pecially in cancers from the gastrointestinal tract. This
susceptibility is attributed to venous drainage of the
gastrointestinal tract via the portal vein and to the liver-
specific microenvironment suitable for colonization by
certain types of tumor. Local therapy, including surgery
and SBRT of liver metastatic lesions, has significantly
improved survival in these patients. Much evidence ex-
ists showing the efficacy of surgical resection of hepatic
metastases from colorectal cancer, with 10-year overall
survival (OS) rates of 17-28%, which is far better than
those of patients treated with systemic therapy [12].
Long-term survival after resection for non-colorectal
cancer liver metastases has also been documented. A
systematic review of >1000 patients with breast cancer
and liver metastasis showed 2-, 3- and 5-year survival
rates of 58-86%, 35-79% and 21-61%, respectively [13].
Liver metastasectomy of neuroendocrine tumors (NET)
has also been shown to benefit most patients (95%) and
prolong survival [14]. A systematic review of NET liver
metastasectomy reported median 5- and 10-year OS
rates of 70.5% and 42%, respectively, and median 1-,
3- and 5-year progression free survival (PFS) rates of
63%, 32% and 29%, respectively, which are much better
than those from other tumor origins. Hepatectomy of me-
tastases from melanoma also nearly doubles survival, with
a median OS of 14 months after surgery increased to
27 months with R0 resection [15]. Summary of hepatic
metastasectomy from selected studies were listed in
Table 1.tudies
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patients with liver oligometastases, unfortunately, only
some patients are eligible for metastasectomy at diagno-
sis [21]. It is difficult to eradicate gross tumors using
conventional radiotherapeutic techniques without ac-
companied radiation-induced liver disease because of
the relative radiosensitivity of the liver [22]. Stereotactic
body radiotherapy allows delivery of ablative doses of ra-
diation to metastatic lesions. The efficacy and tolerability
of SBRT for liver metastasis has been confirmed by
retrospective studies [23-26] showing local control rates
around 80% or higher [27]. At Centre Oscar Lambret, 42
patients with 62 liver metastases were treated with SBRT
at 40 Gy in 4 fractions and 45 Gy in 3 fractions. 1- and
2-year local control rates were 90% and 86%, respectively,
and 1- and 2-year OS rates were 94% and 48%, respect-
ively. In all, 38% of patients suffered grade 1 or 2 toxicity,
and one patient had grade 3 epidermitis. Summary of
SBRT for liver metastasis from selected studies were listed
in Table 2.
Although many reports on SBRT for liver metastases
are retrospective, prospective trials have been initiated
as well. In phase I trials, maximum tolerated doses of
SBRT were determined using a range of therapeutic
doses in various fractions. In all, 60 Gy was well toler-
ated and safe and was commonly used as the therapeutic
dose in phase II clinical trials. 1- and 2-year local control
rates in prospective studies ranged 71-95% and 82-92%,
respectively, with no grade 4–5 liver toxicity and few
grade 3 toxicities [28-34]. Preliminary reports from a
2013 phase II trial of 61 patients with 3 or more lesions
receiving 75 Gy on 3 consecutive days showed a 94% in-
field local response rate at 1-year, median OS of 19 months
and actuarial survival of 83.5% at 12 months. Grade 3 late
toxicity occurred in one patient, with no grade 3 or higher
acute toxicity. SBRT offers an alternative, noninvasive ap-
proach for patients with liver metastases. The outcomes of
serial studies confirm that it is a promising treatmentTable 2 Summary of SBRT for liver metastasis from selected s
Primary tumor type Year No. patients Local control
Mixed (Most colorectal
cancer)
2001 37 81% at 18 month
Mixed 2006 36 93% at 18 months
Mixed (Most colorectal
cancer)
2009 68 1-year local control rate w
Mixed (Most colorectal
cancer)




2011 27 30-, 50-, and 60-Gy cohor
100% at 24 months respe
Mixed 2009 47 1- and 2-year local contro
and 92%modality with efficacy and safety, bringing benefit to pa-
tients with unresectable lesions.
Lung oligometastases
Lung metastasis is also a major cause of cancer death,
and the lung is the primary venous drainage organ for
the entire body except the gastrointestinal tract. The
lung is the most extensively studied organ for cancer
microenvironment because of its susceptibility to metas-
tasis. Local therapy for patients with lung oligometas-
tases is not new and significantly prolongs survival.
Many retrospective surgical studies have shown that pa-
tients with limited metastases can have a long-term sur-
vival, indicating that limited metastasis may be eliminated
in these patients [35-41]. The particular study by Pastor-
ino et al. (1997) is of great importance [35]. They assessed
the long-term results of 5206 cases of lung metastases
from different origins treated with surgery included in the
International Registry of Lung Metastases. The 5-year OS
rate of patients with complete metastasectomy was 36%,
but it was only 13% for those with incomplete resection. A
prospective study including 1720 patients with pulmonary
metastatic melanoma showed that metastasectomy is a
strong predictor of survival with the hazard ratio of 0.5
(95% CI: 0.4-0.6) [40]. Summary of pulmonary metasta-
sectomy from selected studies were listed in Table 3.
SBRT has been shown to prolong OS or even induce a
cure in lung oligometastases, which is especially attract-
ive for patients who refuse or are unsuitable for resec-
tion. Results of retrospective studies have shown 2-year
local control rates ranging 80-90% and 2-year OS rates
ranging 66-84% [48-52]. These results were repeated in
a 2010 systematic review involving 334 patients, in which
the 2-year weighted local control rate was 77.9%, and the
2-year weighted OS rate was 53.7%. Recently, Takahashi
et al. conducted a retrospective analysis of 42 patients
with lung oligo-recurrence who underwent SBRT, 2-year
local control rate and 2-year OS rate were 87% and 65%tudies
Toxicity References
not mentioned [28]
one case of grade 3 soft tissue
toxicity
[29]
as 71% 9% acute grade 3 toxicities and
1% grade 4 toxicity
[30]
l rates were 94% 4 cases of grade ≥3 toxicity [31]
ts were 56%, 89%, and
ctively
one case of grade 3 toxicity [32]
l rates were 95% actuarial rate of grade ≥3 toxicity
was 2%
[33]
Table 3 Summary of pulmonary metastasectomy from selected studies
Primary tumor type Year No. patients 5-year survival (%) 10-year survival (%) References
Melanoma 2007 1720 21 / [40]
Many types 2011 575 46 / [37]
Colorectal carcinoma 2002 165 39.6 37.2 [41]
Colorectal carcinoma 2007 175 53.8 20.6 [42]
Renal cell carcinoma 2002 191 41.5 / [38]
Renal cell carcinoma 2011 202 39 / [43]
Testicular germ cell tumors 1998 157 68 / [44]
Malignant fibrous histiocytoma 2005 103 21 / [45]
Gynecologic cancers 2006 103 46.8 34.3 [46]
Bone sarcoma 2010 52 31 / [47]
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of carbon ion radiotherapy for lung oligo-recurrence were
evaluated in a retrospective study, 3-year local control rate
was 85.4% and 3-year OS rate was 50.1%, without any
grade 3–5 toxicity [54]. The safety and efficacy of SBRT
for lung oligometastases has been confirmed by prospect-
ive phase I and II trials. In one multi-institutional phase I/
II trial, use of SBRT at 48–60 Gy in 3 fractions showed no
dose-limiting toxicities. In all, 60 Gy was delivered in
phase II, and 1- and 2-year actuarial local control rates
were 100% and 96%, respectively. The median survival
was 19 months. Grade 3 toxicity occurred in 8% of pa-
tients with no grade 4 or higher toxicity [55]. Other pro-
spective studies have shown similar results [56,57], which
are comparable to survival after surgery. In summary, in-
creasing evidence proves that SBRT is efficacious and well
tolerated in patients with lung metastases. Summary of
SBRT for lung metastasis from selected studies were listed
in Table 4.
Adrenal oligometastases
Adrenal metastases, mostly lung and renal in origin, are
reported to occur in 13-27% of disseminated malignanciesTable 4 Summary of SBRT for lung metastasis from selected s
Primary tumor type Year No.
patients
Local control
Mixed 2006 50 3-year local control rate
Mixed (Most NSCLC) 2009 124 3-year local control rate
Mixed (Most colorectal
cancer)
2010 10 1- and 2-year local cont
were 48% and 25%
Mixed (Most colorectal
cancer)
2011 44 1- and 2-year local cont
colorectal cancers were
and 72%
Mixed (Most NSCLC) 2012 61 2- and 3- year local con
were 89% and 83.5%
Mixed (Most colorectal
cancer)
2013 32 1-, 2- and 3- year local c
rates were 97%, 92% anat autopsy [61]. Although debates exist on adrenal metas-
tasectomy, several retrospective studies have shown that
both open and laparoscopic adrenalectomy prolongs sur-
vival [62,63]. In a 2012 retrospective study by Zheng et al.,
31/47 patients had adrenal metastasectomy, and survival
rates were significantly higher in patients with surgery
than in patients without surgery (34.2 ± 4.7 vs. 6.3 ±
2.7 months, respectively). Data on SBRT for treating
adrenal metastases is limited. Several studies show that
it is an invasive but effective and safe option [64,65].
Casamassima et al. studied 48 patients with adrenal
metastases who were treated with SBRT at 36 Gy/3
fractions. Actuarial 1- and 2-year local control rates
were 90%, and actuarial OS rates at 1 and 2 years were
39.7% and 14.5%, respectively.
Spinal oligometastases
Bone metastases account for 20% of patients with meta-
static tumors, and the most common site is the axial
skeleton. Spinal metastases often cause pain and dimin-
ished quality of life. Palliative surgery benefit patients
with spinal metastasis by improving quality of life [66,67].
SBRT has emerged as a novel, promising and non-invasivetudies
Toxicity References
83% 35% Grade 1 toxicity, 6.1% grade 2 toxicity,
2% grade 3 toxicity
[51]
83% 17.8% Grade 2 toxicity, 1.2% grade 3 toxicity [48]
rol rates Not mentioned [58]
rol rates in
80%
2 cases of Grade 2 radiation pneumonitis,
1 case of Grade 3 pneumonitis, No Grades
4 radiation pneumonitis
[59]
trol rates one case of grade 3 radiation pneumonitis [52]
ontrol
d 85%
no grade 4 toxicity, 3 cases of grade 3 toxicities,
1 case of grade 2 radiation pneumonitis
[60]
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In a phase I/II trail, 149 patients with 166 non-cord com-
pressing spinal metastases were treated with 27–30 Gy
SBRT, generally in 3 fractions. Actuarial survival rates at 1
and 2 years were 71.9% and 48.8%, respectively. The ac-
tuarial local control rates at 1 and 2 years after SBRT
were 80.5% and 72.4%, respectively. Few grade 3 and
no grade 4 or higher toxicities were observed. Com-
pared to surgery, SBRT may better benefit patients with
prolong survival, pain relief and safety. However, it should
be noted that SBRT is associated with vertebral compres-
sion fractures [70,71].
Long-term follow-up data of oligometastases treated by
SBRT
Although there are no prospective randomized studies
comparing the long-term survival of SBRT and metasta-
sectomy, the recent prospective study by Widder et al.
found that the long-term survival of patients with pul-
monary oligometastases treated with SBRT is not infer-
ior to that of metastasectomy. In this study, the 5-year
OS rates were 41% for metastasectomy and 49% for
SBRT (p =0.43) [72].
Several studies have shown better prognosis in long-
term survivors who had been treated with SBRT. Recently,
de Vin et al. retrospectively studied 309 oligometastatic
cancer patients treated with SBRT. They showed a 5-year
OS rate of 32%, and they identified a subgroup of long-
term survivors with a median survival of 40 (24–63)
months [73]. Moreover, a prospective study by Milano
et al. of 121 patients with oligometastases treated with
SBRT showed a 6-year OS rate of 20%, and they identified
selected long-term breast cancer survivors with a 6-year
OS rate of 47% [74]. Clearly, the key issue for prospective
randomized trials to verify the promising benefit of SBRT
in patients with oligometastases will be how to identify
the most suitable population for radical local treatment.
Clinical factors in selecting patients with oligometastases
The satisfactory outcomes of local therapy for oligome-
tastases strongly suggest the existence of an oligometa-
static phenotype, but the frequency of oligometastases in
various cancer types is unknown, and there are no
standard criteria used to identify these patients. How-
ever, several clinical prognostic factors have been identi-
fied which strongly suggest the oligometastatic state and
aid in selecting patients for aggressive local therapies.
Colorectal cancer
Liver is the most common site of metastasis from colorec-
tal cancer, and more than half of patients with colorectal
cancer will develop liver metastases during the disease
course. As early as the 1980s, a subpopulation of patients
with isolated liver metastases and a better prognosis wasidentified [75], and hepatic resection has become the
standard treatment for resectable liver metastases from
colorectal cancer. Recent data on the efficacy of this surgi-
cal resection has demonstrated a 5-year OS rate of 39-47%
and a 10-year OS rate of 17-28%, which is far better
than for those who received systemic therapy [76,77].
These long-term survivors strongly support the biological
distinction of oligometastases in colorectal cancer.
Simmonds et al. performed a review of 529 independent
studies evaluating the benefit of hepatic resection of oligo-
metastases from colorectal cancer and found a majority of
retrospective studies and an absence of prospective ran-
domized trials [78], indicating the need for further studies
of this population.
Approximately 10-15% of patients with colorectal can-
cer will develop lung metastases, and pulmonary metasta-
sectomy is the standard treatment for resectable lesions.
Evidence suggests that patients with isolated lung metasta-
ses have a better prognosis after resection, with a 5-year
OS rate of 40-61% [79,80]. Salah et al. reviewed 8 retro-
spective studies of pulmonary metastasectomy in 988
colorectal cancer patients, and the 5-year OS rate was
54.3% following the first lung resection [81]. Moreover,
after further stratification into the population into good,
intermediate, and high-risk groups according to three in-
dependent prognostic factors (CEA, disease free interval
and lesion numbers), the 5-year OS were 68.2%, 46.4%
and 26.1%, respectively; in this, the good and intermediate
groups had OS comparable to patients with stage III colo-
rectal cancer.
Although there is a lack of randomized controlled data
on local therapy for metastases from colorectal cancer,
the promising long-term survival suggests a potential
cure in the oligometastatic population, while this sur-
vival is rare in patients with extensive metastases.
Breast cancer
The survival benefit of pulmonary metastasectomy for
patients with breast cancer has been reported in retro-
spective studies, but until recently, no prospective random-
ized trials have been available to validate the existence of
oligometastases in breast cancer and to explore the impact
of local therapy. Recently, Meimarakis et al. studied the
role of metastasectomy in breast cancer patients with oli-
gometastases, at least partially [82]. They reported 5- and
10-year OS rates of 59.6% and 43.0%, respectively, which
were significantly higher than those of patients treated
regularly.
Liver metastases of breast cancer are usually part of
generalized metastases and indicate a poor prognosis
with a median OS of 4–12 months, but selected (<5%)
patients with isolated liver metastases have shown good
long-term survival after metastasectomy of liver lesions.
A systematic review by Bergenfeldt et al. analyzed
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who had undergone metastasectomy and patients who
had received local ablation therapy such as SBRT,
they showed that surgical resection led to 5-year OS
rates of 25-42%, that local ablation therapy had simi-
lar survival results, and R0 resection was a strong
prognostic factor for survival [13].
Non-small cell lung cancer (NSCLC)
A systematic review by Ashworth et al. analyzed 49
retrospective studies of 2176 patients with NSCLC
treated with metastasectomy and found highly variable
survival outcomes, with 5-year OS rates of 10-80% and
more than half of oligometastatic lesions progressing
within 12 months after metastasectomy [83]. Interest-
ingly, two randomized controlled trials, primarily of pa-
tients with NSCLC, have provided compelling evidence
in support of an oligometastatic state. In 1990, Patchell
et al. reported that patients with a single brain metasta-
sis who had undergone metastasectomy plus radiotherapy
had longer survival than those who had received radio-
therapy alone [84]. In a randomized multi-institutional
trial, 333 patients (64% NSCLC) with brain metastases re-
ceived whole-brain radiation therapy with or without an
SBRT boost; results for patients with a single brain metas-
tases showed that the combination therapy group had a
survival advantage compared to the whole-brain radiation
group (median OS 6.5 vs 4.9 months, p =0.039) [85].
Other tumor origins
The different histology of tumors greatly influences
prognosis, and this fact should be taken into account
when determining patient treatment. Studies have shown
that tumors from particular origins have a better prog-
nosis after local therapy. Pulmonary metastases from
germ cell tumors, hepatic metastases from neuroendo-
crine tumors (NET), and breast cancer oligometastases
all have relatively prolonged survival, while hepatic me-
tastasis from gastric cancer has a worse prognosis. A
2011 retrospective study of 575 patients and 708 lesions
by Casiraghi et al. showed that tumor origin predicts
prognosis after pulmonary metastasectomy, with 5-year
survival rates of 46%, 39%, 37% and 90% for epithelial,
sarcoma, melanoma and germ cell cancers, respectively.
Number of metastases in selecting patients with
oligometastases
The number of metastatic lesions is known to influence
prognosis, but the concrete number of lesions has not
been determined. Several important studies confirmed
that 4 metastases is a critical value. A systematic review
of 15 studies by Spelt et al. demonstrated that number
of metastases was a prognostic factor in all prospectivestudies and in 8/11 retrospective studies, and that num-
ber of metastases correlated best with survival [86].
DFI in selecting patients with oligometastases
DFI has generally been considered a prognostic factor in
lung metastases other than liver metastases. The value of
DFI has not been standardized, however, and varies be-
tween 12, 23 and 36 months in different studies. Kanzaki
et al. studied patients with pulmonary metastasectomy
from renal cell carcinoma and demonstrated that a
DFI ≥2 years was associated with a 5-year survival of
58% but that the survival of patients with DFI <2 years
decreased to 26% [87]. DFI has also been found to be
a prognostic factor after pulmonary local therapy.
Pfannschmidt et al. demonstrated a 5-year survival
rate of 24.7% in patients with DFI <23 months com-
pared to 47% for those with DFI >23 months [33].
N stage in selecting patients with oligometastases
Involvement of lymph nodes, also termed N staging, is a
risk factor in several tumor types, particularly in liver
metastases other than pulmonary metastases. Negative
lymph node status predicts a better prognosis than posi-
tive status after local therapy. In a study of 925 patients
by Rees et al. to evaluate factors associated with prognosis
after liver metastasectomy for colorectal cancer, primary
lymph node status was identified as a prognostic factor,
and 5-year survival was 42.2% with lymph node-negative
status and 31.8% with lymph-node-positive status [88].
Scoring systems in selecting patients with oligometastases
Scoring systems, which aim to predict prognosis before
local therapy, are useful because individual patients have
different prognostic factors. Myrddin et al. performed a
prospective study of 929 patients to identify prognostic
factors after hepatic resection for metastatic colorectal
cancer [88], and the Basingstoke Predictive Index was
created based on the following prognostic factors: pri-
mary lymph node status, primary tumor differentiation,
CEA level at hepatectomy, metastatic number, largest
tumor diameter and extrahepatic metastatic disease. Pa-
tients were given a total score based on the prognostic
factors and were divided into the following groups: 0, 5,
10, 15, 20, 25, and 30. Five-year survival in patients with
the lowest scores was 66%, decreasing to only 2% in pa-
tients with the highest scores. Similar results have been
observed in other scoring systems, including Risk score,
the Memorial Sloan Kettering Cancer Center clinical risk
score and simplified cancer staging systems [89-91].
MiroRNA signature in selecting patients with
oligometastases
MicroRNA is known to regulate proliferation and apop-
tosis in cancer development, and microRNA expression
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than coding gene profiles. Emerging evidence indicates
that microRNA profiles could be a useful tool to distin-
guish oligometastasis from polymetastasis. Recently,
Lussier et al. analyzed microRNA expression patterns from
lung metastasis samples of patients with 1–5 metastatic
tumors resected with curative intent [92] and identified
distinct microRNA profiles between patients with the
highest and lowest rates of recurrence. Another clinical/
pathologic correlation study indicated that microRNA-
200c expression was able accurately to characterize
patients with clinically limited metastases into two
phenotypes-those whose disease progressed to wide-
spread, polymetastatic recurrence and those with clinic-
ally limited disease or oligometastatic recurrence [92].
Conclusions
Given the abundant clinical and biological evidence sup-
porting the oligometastatic state, we infer that oligome-
tastasis is more than a mirage. As understanding of the
biology of metastases increases, improved biomarkers to
accurately identify patients with oligometastases will be
generated, allowing better selection for locally ablative
therapies. Furthermore, prospective trials will be needed
to clarify the criteria for selecting patients with oligome-
tastases from each specific cancer type, and randomized
trials comparing the efficacy and safety of different treat-
ment modalities including SBRT or surgery will also be
needed to generate guidelines for the treatment of oligo-
metastasis. With the advance of molecular and clinical
medicine, the oligometastasis mirage might be converted
to a paradigm of cancer treatment.
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